Cholestatic jaundice as a result of combination designer supplement ingestion

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages

  Vilella, Antonia L ^a,b   Limsuwat, Chok ^c   Williams, Dustyn R ^d   Seifert, Charles F ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COLESTYRAMINE; CREATINE; CREATININE; HYDROXYZINE; INFUSION FLUID; METHYLPREDNISOLONE; PANCREAS ENZYME; PERFORMANCE ENHANCING SUBSTANCE; PREDNISONE; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FOLLOW UP; GENERAL PRACTITIONER; HERBAL MEDICINE; HISPANIC; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; MALE; MEDICAL HISTORY; OBSTRUCTIVE JAUNDICE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN INTAKE; PRURITUS; UREA NITROGEN BLOOD LEVEL; WHEY;

ANABOLIC AGENTS; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; HUMANS; JAUNDICE, OBSTRUCTIVE; MALE; MIDDLE AGED; PLANT PREPARATIONS;

EID: 84880052842     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R405     Document Type: Article

References (18)

1. Gahche J, Bailey R, Burt V, et al. Dietary supplement use among US adults has increased since NHANES III (1988-1994). NCHS data brief, no 61. Hyattsville, MD: National Center for Health Statistics, 2011. www.cdc.gov/nchs/data/databriefs/db61.pdf (accessed 2011 Nov 23).
2. Institute of Medicine (US) Committee on dietary supplement use by military personnel. Greenwood MRC, Oria M, eds. In: Use of dietary supplements by military personnel. Washington, DC: National Academies Press; 2008 2, Recent survey findings and implications for future surveys of dietary supplement use. www.ncbi.nlm.nih.gov/books/NBK3967/ (accessed 2011 Nov 25).
3. Food and Drug Administration. FDA warns consumers not to use body building products marketed as containing steroids or steroid-like substances. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ ucm174060.htm (accessed 2011 Nov 20).
4. Koert W, de Groot A. Steroids in designer supplements. In: About the anabolics book. www.ergogenics.org/anabolenboek/index19en.html (accessed 2011 Nov 21).
5. ProhormoneDB. Prohormone and supplement ingredients. www.pro hormonedb.com (accessed 2011 Nov 21).
6. Whitt KN, Ward SC, Deniz K, Liu L, Odin JA, Qin L. Cholestatic liver injury associated with whey protein and creatine supplements. Semin Liver Dis 2008;28:226-32. doi: 10.1055/s-2008-1073122
7. Shah NL, Zacharias I, Khettry U, Afdhal N, Gordon FD. Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol 2008;6:255-8. doi: 10.1016/j.cgh.2007.11.010
8. Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin Gastroenterol Hepatol 2007;5:809-12. doi: 10.1016/j.cgh.2007.02.036
9. Jasiurkowski B, Raj J, Wisinger D, Carlson R, Zou L, Nadir A. Cholestatic jaundice and IgA nephropathy induced by OTC muscle building agent Superdrol. Am J Gastroenterol 2006;101:2659-62. doi: 10.1111/j.1572-0241.2006.00735.x
10. Drug Enforcement Administration. Classification of two steroids, pro stano-zol and methasterone, as schedule III anabolic steroids under the Controlled Substances Act (FR Doc No: 2011-30081). Washington, DC: Government Printing Office, 2011;76: 72355-762. www.gpo.gov/fdsys/pkg/FR-2011-11-23/pdf/2011-30081.pdf (accessed 2011 May 25).
11. Štimac D, Milić S, Dintinjana RD, Kovač D, Ristić S. Androgenic/anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002;35:350-2. doi: 10.1097/00004836-200210000-00013
12. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731-9. doi: 10.1056/NEJMra052270
13. Hall RC, Hall RC. Abuse of supraphysiologic doses of anabolic steroids. South Med J 2005;98:550-5. doi: 10.1097/01.SMJ.0000157531.04472.B2
14. Sánchez-Osorio M, Duarte-Rojo A, Martínez-Benítez B, Torre A, Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int 2008;28:278-82. doi: 10.1111/j.1478-3231.2007.01579.x
15. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
16. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6.
17. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51: 237-67. doi: 10.1016/j.jhep.2009.04.009
18. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006; 10:207-17. doi: 10.1016/j.cld.2006.05.009